Literature DB >> 29061715

Statin initiations and QRISK2 scoring in UK general practice: a THIN database study.

Samuel Finnikin1, Ronan Ryan1, Tom Marshall1.   

Abstract

BACKGROUND: Statin prescribing should be based on cardiovascular disease (CVD) risk, but evidence suggests overtreatment of low-risk groups and undertreatment of high-risk groups. AIM: To investigate the relationship between CVD risk scoring in primary care and initiation of statins for the primary prevention of CVD, and the effect of changes to the National Institute for Health and Care Excellence (NICE) guidance in 2014. DESIGN AND
SETTING: Historical cohort study using UK electronic primary care records.
METHOD: A cohort was created of statin-naïve patients without CVD between 1 January 2000 and 31 December 2015. CVD risk scores (calculated using QRISK2 available from 2012) and statin initiations were identified. Rates of CVD risk score recording were calculated and relationships between CVD risk category (low-, intermediate-, and high-risk: <10%, 10-19.9%, and ≥20% 10-year CVD risk) and statin initiation were analysed.
RESULTS: A total of 1.4 million patients were identified from 248 practices. Of these, 151 788 had a recorded CVD risk score since 2012 (10.67%) and 217 860 were initiated on a statin (15.31%). Among patients initiated on a statin after 2012, 27.1% had a documented QRISK2 score: 2.7% of low-risk, 13.8% of intermediate-risk, and 35.0% of high-risk patients were initiated on statins. Statin initiation rates halved from a peak in 2006. After the 2014 NICE guidelines, statin initiation rates declined in high-risk patients but increased in intermediate-risk patients.
CONCLUSION: Most patients initiated on statins had no QRISK2 score recorded. Most patients at high risk of CVD were not initiated on statins. One in six statin initiations were to low-risk patients indicating significant overtreatment. Initiations of statins in intermediate-risk patients rose after NICE guidelines were updated in 2014. © British Journal of General Practice 2017.

Entities:  

Keywords:  clinical guidance; general practice; hydroxymethylglutaryl-CoA reductase inhibitors; primary prevention; risk assessment; statins

Mesh:

Substances:

Year:  2017        PMID: 29061715      PMCID: PMC5697558          DOI: 10.3399/bjgp17X693485

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  23 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

2.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

Review 3.  The effect of giving global coronary risk information to adults: a systematic review.

Authors:  Stacey L Sheridan; Anthony J Viera; Mori J Krantz; Christa L Ice; Lesley E Steinman; Karen E Peters; Laurie A Kopin; Danielle Lungelow
Journal:  Arch Intern Med       Date:  2010-02-08

4.  Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates.

Authors:  Betina T Blak; Mary Thompson; Hassy Dattani; Alison Bourke
Journal:  Inform Prim Care       Date:  2011

Review 5.  Risk scoring for the primary prevention of cardiovascular disease.

Authors:  Kunal N Karmali; Stephen D Persell; Pablo Perel; Donald M Lloyd-Jones; Mark A Berendsen; Mark D Huffman
Journal:  Cochrane Database Syst Rev       Date:  2017-03-14

6.  Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.

Authors:  Julia Hippisley-Cox; Carol Coupland; Yana Vinogradova; John Robson; Rubin Minhas; Aziz Sheikh; Peter Brindle
Journal:  BMJ       Date:  2008-06-23

7.  European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Eur Heart J       Date:  2012-05-03       Impact factor: 29.983

8.  Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data.

Authors:  Anthony Matthews; Emily Herrett; Antonio Gasparrini; Tjeerd Van Staa; Ben Goldacre; Liam Smeeth; Krishnan Bhaskaran
Journal:  BMJ       Date:  2016-06-28

9.  Time to improve statin prescription guidelines in low-risk patients?

Authors:  Jan W Balder; Jeroen K de Vries; Douwe J Mulder; Pieter W Kamphuisen
Journal:  Eur J Prev Cardiol       Date:  2017-03-14       Impact factor: 7.804

10.  Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data.

Authors:  Aidan G O'Keeffe; Irwin Nazareth; Irene Petersen
Journal:  Clin Epidemiol       Date:  2016-05-27       Impact factor: 4.790

View more
  18 in total

1.  Use of statins in the elderly according to age and indication-a cross-sectional population-based register study.

Authors:  Helena Sundvall; Johan Fastbom; Susanna M Wallerstedt; Sigurd Vitols
Journal:  Eur J Clin Pharmacol       Date:  2019-03-03       Impact factor: 2.953

2.  Polygenic risk scores: improving the prediction of future disease or added complexity?

Authors:  Aya Ayoub; Jana McHugh; Judith Hayward; Imran Rafi; Nadeem Qureshi
Journal:  Br J Gen Pract       Date:  2022-07-28       Impact factor: 6.302

Review 3.  Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.

Authors:  Timothy Mark Reynolds; Alison Pottle; Sadat H Quoraishi
Journal:  Vasc Health Risk Manag       Date:  2021-05-21

4.  Regularity and Continuity of GP Contacts and Use of Statins Amongst People at Risk of Cardiovascular Events.

Authors:  David Youens; Jenny Doust; Suzanne Robinson; Rachael Moorin
Journal:  J Gen Intern Med       Date:  2021-03-02       Impact factor: 6.473

5.  Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease.

Authors:  Paula Byrne; John Cullinan; Catríona Murphy; Susan M Smith
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

6.  The effects of age on clinical characteristics, hospitalization and mortality of patients with influenza-related illness at a tertiary care centre in Malaysia.

Authors:  Pui Li Wong; Hoe Leong Sii; Chun Keat P'ng; Soon Sean Ee; Xiang Yong Oong; Kim Tien Ng; Nik Sherina Hanafi; Kok Keng Tee; Maw Pin Tan
Journal:  Influenza Other Respir Viruses       Date:  2020-02-05       Impact factor: 4.380

7.  Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy.

Authors:  Mahima Kapoor; Jennifer Spillane; Christina Englezou; Scherezade Sarri-Gonzalez; Robert Bell; Alexander Rossor; Hadi Manji; Mary M Reilly; Michael P Lunn; Aisling Carr
Journal:  Neurology       Date:  2019-12-18       Impact factor: 9.910

8.  Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006-2019: A cohort study.

Authors:  Sophie V Eastwood; Rohini Mathur; Naveed Sattar; Liam Smeeth; Krishnan Bhaskaran; Nishi Chaturvedi
Journal:  PLoS Med       Date:  2021-06-29       Impact factor: 11.613

9.  Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings.

Authors:  Mohamed Hassan Elnaem; Mohamad Haniki Nik Mohamed; Hasniza Zaman Huri; Azarisman Shah Mohd Shah
Journal:  Ther Clin Risk Manag       Date:  2019-01-18       Impact factor: 2.423

10.  What are the cost-savings and health benefits of improving detection and management for six high cardiovascular risk conditions in England? An economic evaluation.

Authors:  Chloe Thomas; Alan Brennan; Edward Goka; Hazel Y Squires; Gilly Brenner; David Bagguley; Helen Buckley Woods; Michael Gillett; Joanna Leaviss; Mark Clowes; Laura Heathcote; Katy Cooper; Penny Breeze
Journal:  BMJ Open       Date:  2020-09-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.